NITRO-DUR 0.4 0.4 MG — DIN 01911902
NITROGLYCERIN : 0.4 MG · USPHARMA LTD · PATCH (EXTENDED RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is NITRO-DUR 0.4?
NITRO-DUR 0.4 0.4 MG contains NITROGLYCERIN : 0.4 MG. It is listed in the Health Canada Drug Product Database under DIN 01911902, held by USPHARMA LTD, supplied as PATCH (EXTENDED RELEASE) for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 12-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NITRO-DUR 0.4 used for?
NITRO-DUR (nitroglycerin) used intermittently is indicated for the prevention of anginal attacks in patients with stable angina pectoris associated with coronary artery disease. It can be used in conjunction with other antianginal agents such as beta-blockers and/or calcium antagonists. NITRO-DUR is not intended for the immediate relief of acute attacks of angina pectoris. Sublingual nitroglycerin preparations should be used for this purpose.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Glyceryl Trinitrate cost around the world?
Glyceryl Trinitrate is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United Kingdom | hospital | 12 | 12 | GBP███.██ |
| Australia | ex-manufacturer | 4 | 9 | AUD███.██ |
| Saudi Arabia | public | 5 | 8 | SAR███.██ |
| Luxembourg | reimbursement | 7 | 7 | EUR███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| South Africa | single exit price | 3 | 4 | ZAR███.██ |
| Bahrain | retail (max) | 3 | 3 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 2 | 2 | CZK███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 1 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
53 pack listings across 43 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Glyceryl Trinitrate pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Glyceryl Trinitrate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
20 holders have a Canadian DIN containing Glyceryl Trinitrate, across 39 DINs, of which 18 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MYLAN PHARMACEUTICALS ULC | 5 | 4 | MYLAN-NITRO PATCH 0.2, MYLAN-NITRO PATCH 0.4, MYLAN-NITRO PATCH 0.6, MYLAN-NITRO PATCH 0.8, MYLAN-NITRO SUBLINGUAL SPRAY | Sourceable in Canada |
| USPHARMA LTD | 4 | 4 | NITRO-DUR 0.2, NITRO-DUR 0.4, NITRO-DUR 0.6, NITRO-DUR 0.8 | Sourceable in Canada |
| ENDO OPERATIONS LTD. | 3 | 3 | TRINIPATCH 0.2, TRINIPATCH 0.4, TRINIPATCH 0.6 | Sourceable in Canada |
| BAXTER CORPORATION | 3 | 2 | NITROGLYCERIN IN 5% DEXTROSE INJ.-100MCG/ML, NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML, NITROGLYCERIN IN 5% DEXTROSE INJ.-400MCG/ML | Sourceable in Canada |
| BGP PHARMA ULC | 2 | 2 | NITROSTAT | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 2 | 1 | NITROJECT, NITROJECT INJ 1MG/ML | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | NITROGLYCERIN INJECTION USP, RHO-NITRO PUMPSPRAY | Sourceable in Canada |
| SANOFI-AVENTIS CANADA INC | 1 | 1 | NITROLINGUAL PUMPSPRAY | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 4 | 0 | TRANSDERM-NITRO 0.2, TRANSDERM-NITRO 0.4, TRANSDERM-NITRO 0.6, TRANSDERM-NITRO 0.8 | No marketed DIN |
| VALEANT CANADA LP / VALEANT CANADA S.E.C. | 3 | 0 | MINITRAN | No marketed DIN |
| ASTRA PHARMA INC. | 1 | 0 | NITROGARD-SR TAB 1MG | No marketed DIN |
| METRO PHARM INC. | 1 | 0 | NITRONG SR SRT 2.6MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.4 MG |
|---|---|
| Dosage form | PATCH (EXTENDED RELEASE) |
| Route | TRANSDERMAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Glyceryl Trinitrate |
|---|---|
| ATC code | C01DA02 |
| AHFS class | 24:12.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01911902 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1911902 |
| Brand name | NITRO-DUR 0.4 |
| Generic / active ingredient | NITROGLYCERIN : 0.4 MG |
| Market authorization holder | USPHARMA LTD |
| Health Canada schedule | Ethical |
| ATC code | C01DA02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01DA |
| Current status | MARKETED |
| Status date | 12-Jul-2018 |
| Original market date | 1991-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
18 of 39 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYLAN-NITRO PATCH 0.2 | 0.2 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407442 |
| MYLAN-NITRO PATCH 0.4 | 0.4 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407450 |
| MYLAN-NITRO PATCH 0.6 | 0.6 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407469 |
| MYLAN-NITRO PATCH 0.8 | 0.8 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407477 |
| NITRO-DUR 0.2 | 0.2 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 01911910 |
| NITRO-DUR 0.6 | 0.6 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 01911929 |
| NITRO-DUR 0.8 | 0.8 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 02011271 |
| NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02145308 |
| NITROGLYCERIN IN 5% DEXTROSE INJ.-400MCG/ML | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02145316 |
| NITROJECT | 50 MG / 10 ML | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 00778869 |
2 · Same class — other molecules in ATC C01DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Glyceryl Trinitrate | APO-NITROGLYCERIN · MINITRAN · MINITRAN - PATCH TRD 72MG/26.6 SQ CM · MYLAN-NITRO PATCH 0.2 · +31 more | 39 | 18 | Yes |
| Isosorbide Mononitrate | APO-ISMN · DOM-ISMN · IMDUR · ISMN · +4 more | 8 | 3 | Yes |
| Isosorbide Dinitrate | CEDOCARD-SR SRT 20MG · CEDOCARD-SR SRT 40MG · CORADUR TAB 20MG · CORONEX · +16 more | 25 | 2 | Yes |
| Pentaerithrityl Tetranitrate | PERITRATE SA 80MG TAB · PERITRATE TAB 10MG · PERITRATE TAB 20MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01DX | Nesiritide · Vericiguat | 4 | 3 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NITRO-DUR 0.4 called?
The same molecule, Glyceryl Trinitrate, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| NITRO-DUR | Latin | Saudi Arabia |
| Nitrolingual Pumpspray | Latin | Australia |
| Rectogesic | Latin | Bahrain, Iceland |
| Nitrocine | Latin | South Africa |
| Angised | Latin | South Africa |
| GLYTRIN Sublingual Spray | Latin | United Arab Emirates |
| NITROGLYCERIN SLOVAKOFARMA | Latin | Czechia |
| Nitrolingual | Latin | South Africa |
| Nitrolingual®-Spray | Latin | United Arab Emirates |
| NITROMINT | Latin | Czechia |
| Nitronal® aqueous | Latin | United Arab Emirates |
| Rectogesic® | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.